Format

Send to

Choose Destination
Acta Medica (Hradec Kralove). 2017;60(1):5-11. doi: 10.14712/18059694.2017.44. Epub 2017 Apr 11.

Anthelmintic Flubendazole and Its Potential Use in Anticancer Therapy.

Author information

1
Charles University, Faculty of Medicine in Hradec Králové, Department of Medical Biology and Genetics, Hradec Králové, Czech Republic.
2
Charles University, Faculty of Pharmacy in Hradec Králové, Department of Pharmacology, Hradec Králové, Czech Republic.
3
Charles University, Faculty of Medicine in Hradec Králové, Department of Medical Biology and Genetics, Hradec Králové, Czech Republic. rudolf@lfhk.cuni.cz.

Abstract

Flubendazole is a widely used anthelmintic drug belonging to benzimidazole group. The molecular mechanism of action of flubendazole is based on its specific binding to tubulin, which results in disruption of microtubule structure and function, and in the interference with the microtubule-mediated transport of secretory vesicles in absorptive tissues of helminths. The microtubule-disrupting properties of benzimidazole derivatives raised recently interest in these compounds as possible anti-cancer agents. In this minireview flubendazole effects towards selected human malignant cells including myeloma, leukemia, neuroblastoma, breast cancer, colorectal cancer and melanoma are discussed along with basic data on its pharmacokinetics, metabolism and toxicity.

KEYWORDS:

anti-cancer treatment; benzimidazole carbamate; flubendazole; melanoma; microtubules; mitotic catastrophe

PMID:
28399389
DOI:
10.14712/18059694.2017.44
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for DDS on behalf of Universitas Carolina
Loading ...
Support Center